Skip to main content
NCBI home page
American Journal of Alzheimer's Disease and Other Dementias logoLink to American Journal of Alzheimer's Disease and Other Dementias
. 2006 Mar-Apr;21(2):113–118. doi: 10.1177/153331750602100211

Herbal medicine in the treatment of Alzheimer's disease

Shahin Akhondzadeh 1, Seyed Hesameddin Abbasi 2
PMCID: PMC10833269  PMID: 16634467

Abstract

Alzheimer s disease (AD) is characterized by profound memory loss sufficient to interfere with social and occupationalfunctioning. It is the most common form of dementia, affecting more than 20 million people worldwide. AD is characterized by an insidious loss of memory, associated functional decline, and behavioral disturbances. Patients may live for more than a decade after they are diagnosed with AD, making it the leading cause of disability in the elderly. The incidence of AD rangesfrom I to 4 percent of the population per year, rising from its lowest level at ages 65 to 70 years to rates that may approach 6 percent for those over the age of 85 years. The first neurotransmitter defect discovered in AD involved acetylcholine (A Ch). As cholinergic function is requiredfor short-term memory, the cholinergic deficit in AD was also believed to be responsible for much of the short-term memory deficit. Clinical drug trials in patients with AD have focused on drugs that augment levels of A Ch in the brain to compensate for the loss of cholinergic function. These drugs have included ACh precursors, muscarinic agonists, nicotinic agonists, and acetylcholinesterase inhibitors. The most highly developed and successful approaches to date have employed acetylcholinestrase inhibition. Although some Food and Drug Administration-approved drugs are available for the treatment ofAlzheimer's disease, the outcomes are often unsatisfactory, and there is a place for alternative medicine, in particular, herbal medicine. This paper reviews the clinical effects of a number of commonly used types of herbal medicines for the treatment ofAD.

Keywords: Alzheimer's disease, Ginkgo biloba, herbal medicine, Melissa officinalis, Salvia officinalis

Full Text

The Full Text of this article is available as a PDF (1.3 MB).

Contributor Information

Shahin Akhondzadeh, Psychiatric Research Center Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Seyed Hesameddin Abbasi, Research Unit, Tehran Heart Center Tehran University of Medical Sciences, Tehran, Iran; National Iranian Oil Company. Central Hospital. Tehran, Iran.

References

  1. 1. Katzman R: The prevalence and malignancy of Alzheimer's disease. A major killer. Arch Neurol. 1976; 33: 217-218. [DOI] [PubMed] [Google Scholar]
  2. 2. Evans DA, Funkenstein HH, Albert MS: Prevalence of Alzheimer's disease in a community population of older persons: Higher than previously reported. JAMA. 1989; 262: 2551-2556. [PubMed] [Google Scholar]
  3. 3. Geldmacher DS, Whitehouse PJ: Differential diagnosis of Alzheimer's disease. Neurology. 1997; 48(Suppl 6): S2-S9. [DOI] [PubMed] [Google Scholar]
  4. 4. World Health Organization: The ICD-JIO Classification of Mental and Behavioral Disorders. Geneva: World Health Organization, 1992. [Google Scholar]
  5. 5. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994. [Google Scholar]
  6. 6. McKhann G. Drachman D, Folstein M, et al.: Clinical diagnosis of AD: Report of NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on AD. Neuiology. 1984; 34: 939-944. [DOI] [PubMed] [Google Scholar]
  7. 7. Schneiders LS: An overview of rating scales used in dementia. Alzheimer Insights. 1996; 2: 1-7. [Google Scholar]
  8. 8. Selkoe DJ: Amyloid beta-protein and genetics of Alzheimer's disease. JBiol Chem. 1996; 27: 18295-18298. [DOI] [PubMed] [Google Scholar]
  9. 9. Lue LF, Kuo YM, Roher AE: Soluble amyloid beta peptide concentration as a predictor of synaptic changes in Alzheimer's disease. Am J Pathol. 1999; 155: 853-862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. 10. Francis PT, Palmer AM, Snape M, et al.: The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol,Veurozsurg Psjchiatrjl 1999; 54: 137-147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. 11. Wright CI, Geula C, Mesulam MM: Neurological cholinesterase in the normal brain and in Alzheimer's disease: Relation to plaques, tangles, and patterns of selective vulnerability. Ann Neurol. 1993; 34: 373-384. [DOI] [PubMed] [Google Scholar]
  12. 12. Davies P, Maloney AJ: Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976; 2: 1457-1459. [DOI] [PubMed] [Google Scholar]
  13. 13. Livingston G. Katona C: How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis. Int J Geriatric Psychiatry 2000; 15: 203-207. [DOI] [PubMed] [Google Scholar]
  14. 14. Giacobini E: Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer's disease. Alzheimer Dis Assoc Disord. 2000; 14: S3-S11. [DOI] [PubMed] [Google Scholar]
  15. 15. Nordberg A, Svensson AL: Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology. Drug Safey. 1998; 19: 465-480. [DOI] [PubMed] [Google Scholar]
  16. 16. Weinstock M: Selectivity of cholinesterase inhibition: Clinical implication for the treatment of Alzheimer's Disease. CNS Drugs. 1999; 12: 307-303. [Google Scholar]
  17. 17. Bullock R: Drug treatment in dementia. Curr Opin Psychiatry 2001; 14: 349-353. [Google Scholar]
  18. 18. Bullock R: New drugs for Alzheimer's disease and other dementias. Br JPsychiatry. 2002; 180: 135-139. [DOI] [PubMed] [Google Scholar]
  19. 19. Keltner NL, Beth Williams SN: Memantine: A new approach to Alzheimer's disease. Perspect Psychiatric Care. 2004; 40: 123-124. [DOI] [PubMed] [Google Scholar]
  20. 20. Akhondzadeh S, Noroozian M: Alzheimer's disease: Pathophysiology and pharmacotherapy. IDrugs. 2002; 4: 1167-1172. [PubMed] [Google Scholar]
  21. 21. Bullock R: New drugs for Alzheimer's disease and other dementias. Br J Psychiatry. 2002; 180: 135-139. [DOI] [PubMed] [Google Scholar]
  22. 22. Shadlen MF, Larson EB: What's new in Alzheimer's disease treatment? Reasons for optimism about future pharmacologic options. Postgrad Med. 1999; 105: 109-118. [DOI] [PubMed] [Google Scholar]
  23. 23. Mayeux R, Sano M: Treatment of Alzheimer's disease. NEngl J Med. 1999; 34: 1670-1679. [DOI] [PubMed] [Google Scholar]
  24. 24. Bush Al: Therapeutic targets in the biology of Alzheimer's disease. Curr Opin Psychiatry. 2001; 14: 341-348. [Google Scholar]
  25. 25. Raskind MA, Peskind ER, Wessel T: Galantamine in AD: A six month randomized placebo-controlled trial with a six month extension. Neurology. 2000; 54: 2261-2268. [DOI] [PubMed] [Google Scholar]
  26. 26. Kanowski S, Hoerr R: Proof of the efficacy of the Ginkgo biloba special extract egb76 1 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type of multi-infarct dementia. Phytomedicine. 1997; 4: 215-222. [DOI] [PubMed] [Google Scholar]
  27. 27. Le Bars PL, Katz MM, Berman N, et al.: A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA. 1997; 278: 1327-1332. [DOI] [PubMed] [Google Scholar]
  28. 28. De Feudis FV: Ginkgo biloba Extract EGb761. Pharmacological Activities and Clinical Applications. Paris: Elsevier, 1991. [Google Scholar]
  29. 29. Kleijnen J: Ginkgo biloba. Lancet 1992; 340: 1136-1139. [DOI] [PubMed] [Google Scholar]
  30. 30. Wettstein A: Cholinesterase inhibitors and ginkgo extracts-are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration. Phytomedicine. 2000; 6: 393-401. [PubMed] [Google Scholar]
  31. 31. Dore S, Bastianetto S, Kar S, et al.:.Protective and rescuing abilities of IGF-I and some putative free radical scavengers against betaamyloid-inducing toxicity in neurons. Ann N YAcad Sci. 1999; 890: 356-364. [DOI] [PubMed] [Google Scholar]
  32. 32. Kanowski S, Hoerr R: Ginkgo biloba extract EGb 761 in dementia: Intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry. 2003; 36: 297-303. [DOI] [PubMed] [Google Scholar]
  33. 33. Schulz V: Ginkgo extract or cholinesterase inhibitors in patients with dementia: What clinical trials and guidelines fail to consider. Phytomedicine. 2003; 10(Suppl) 14-14: 74-79. [DOI] [PubMed] [Google Scholar]
  34. 34. Kurz A, Van Baelen B: Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: A review based on meta-analyses by the Cochrane collaboration. Dementia Geriatr Cogn Disord. 2004; 18: 217-226. [DOI] [PubMed] [Google Scholar]
  35. 35. Xu SS, Gao ZX, Weng Z: Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Zhongguo Yao Li XueBao. 1995; 16: 391-395. [PubMed] [Google Scholar]
  36. 36. Zhang RW, Tang XC, Han YY: Drug evaluation of huperzine A in the treatment of senile memory disorders [in Chinese; English abstract]. Zhongguo Yao LiXue Bao. 1991; 12: 250-252. [PubMed] [Google Scholar]
  37. 37. Zhang Z, Wang X, Chen Q: Clinical efficacy and safety of huperzine alpha in treatment of mild to moderate Alzheimer disease: A placebo-controlled, double-blind, randomized trial. Zhonghua Yi XueZaZhi. 2002; 82: 941-944. [PubMed] [Google Scholar]
  38. 38. Xu SS, Cai ZY, Qu ZW: Huperzine-A in capsules and tablets for treating patients with Alzheimer disease. Zhongguo Yao Li Xue Bao. 1999; 20: 486-490. [PubMed] [Google Scholar]
  39. 39. Szatmari SZ, Whitehouse PJ: Vinpocetine for cognitive impairment and dementia;. Cochrane Database Syst Rev. 2003; CD003 119-119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. 40. Hindmarch I, Fuchs HH, Erzigkeit H: Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol. 1991; 6: 31-43. [DOI] [PubMed] [Google Scholar]
  41. 41. Balestreri R, Fontana L, Astengo F: A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. JAm Geriatr Soc. 1987; 35: 425-430. [DOI] [PubMed] [Google Scholar]
  42. 42. Fenzl E, Apecechea M, Schaltenbrand R: Efficacy and tolerance of vinpocetine administered intravenously, in addition of standard therapy, to patients suffering from an apoplectic insult. In Krieglstein J (ed): Pharmacology of Cerebral Ischemia. Proceedings of the International Symposium on Pharmacology of Cerebral Ischemia. New York: Elsevier Science Publishers; 1986: 430-434. [Google Scholar]
  43. 43. Manconi E, Binaghi F, Pitzus F: A double-blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative origin. Curr Ther Res Clin Exp. 1986; 30: 702-709. [Google Scholar]
  44. 44. Peruzza M, DeJacobis M: A double-blind placebo controlled evaluation of the efficacy and safety of vinpocetine in the treatment of patients with chronic vascular or degenerative senile cerebral dysfunction. Adv Ther. 1986; 3: 201-209. [Google Scholar]
  45. 45. Blaha L, Erzigkeit H, Adamczyk A: Clinical evidence of the effectiveness of vinpocetine in the treatment of organic psychosyndrome. Hum Psychopharmacol. 1989; 4: 103-111. [Google Scholar]
  46. 46. Perry EK, Pikering AT, Wang WW, et al.: Medicinal plants and Alzheimer's disease: Integrating ethnobotanical and contemporary scientific evidence. JAltern Complement Med 1998; 4: 419-428. [DOI] [PubMed] [Google Scholar]
  47. 47. Perry EK, Pikering AT, Wang WW, et al.: Medicinal plants and Alzheimer's disease: From etnobotany to phytotherapy. J Pharm Pharmacol. 1999; 51: 527-534. [DOI] [PubMed] [Google Scholar]
  48. 48. Kennedy DO, Scholey AB, Tildesley NTJ, et al.: Modulation of mood and cognitive performance following acute administration of Melissa officinalis lemon balm. Pharmacol Biochem Behav. 2002; 72: 953-964. [DOI] [PubMed] [Google Scholar]
  49. 49. Akhondzadeh S, Noroozian M, Mohammadi M, et al.: Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: A double blind, randomised, placebo controlled trial. JNeurol Neurosurg Psychiatry. 2003; 74: 863-866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. 50. Akhondzadeh S, Noroozian M, Mohammadi M, et al.: Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: A double blind, randomized and placebo-controlled trial. J Clin Pharm Ther 2003; 28: 53-59. [DOI] [PubMed] [Google Scholar]
  51. 51. Wake G, Court J, Pikering A, et al.: CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory. JEthnopharmacol. 2000; 69: 105-114. [DOI] [PubMed] [Google Scholar]
  52. 52. Schulz V, Hansel R, Tyler VE: Rational Phytotherapy. A Physicians' Guide to Herbal Medicine, 3rd ed. Berlin: Springerverlag, 1998. [Google Scholar]

Articles from American Journal of Alzheimer's Disease and Other Dementias are provided here courtesy of SAGE Publications

RESOURCES